Tang Z - Search Results

1

No QTc Prolongation With Zanubrutinib: Results of Concentration-QTc Analysis From a Thorough QT Study in Healthy Subjects.

Mu S, Darpo B, Tang Z, Novotny W, Tawashi M, Xue H, Willett M, Lin L, Sahasranaman S, Ou YC. Mu S, et al. Among authors: tang z. Clin Transl Sci. 2020 Sep;13(5):923-931. doi: 10.1111/cts.12779. Epub 2020 Apr 8. Clin Transl Sci. 2020. PMID: 32144955 Free PMC article. Clinical Trial.

2

Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.

Tam CS, Trotman J, Opat S, Burger JA, Cull G, Gottlieb D, Harrup R, Johnston PB, Marlton P, Munoz J, Seymour JF, Simpson D, Tedeschi A, Elstrom R, Yu Y, Tang Z, Han L, Huang J, Novotny W, Wang L, Roberts AW. Tam CS, et al. Among authors: tang z. Blood. 2019 Sep 12;134(11):851-859. doi: 10.1182/blood.2019001160. Epub 2019 Jul 24. Blood. 2019. PMID: 31340982 Free PMC article. Clinical Trial.

3

Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects.

Mu S, Tang Z, Novotny W, Tawashi M, Li TK, Ou Y, Sahasranaman S. Mu S, et al. Among authors: tang z. Cancer Chemother Pharmacol. 2020 Feb;85(2):391-399. doi: 10.1007/s00280-019-04015-w. Epub 2019 Dec 26. Cancer Chemother Pharmacol. 2020. PMID: 31875923 Free PMC article.

4

A phase 1, open-label, single-dose study of the pharmacokinetics of zanubrutinib in subjects with varying degrees of hepatic impairment.

Ou YC, Preston RA, Marbury TC, Tang Z, Novotny W, Tawashi M, Li TK, Sahasranaman S. Ou YC, et al. Among authors: tang z. Leuk Lymphoma. 2020 Jun;61(6):1355-1363. doi: 10.1080/10428194.2020.1719097. Epub 2020 Feb 7. Leuk Lymphoma. 2020. PMID: 32031037 Clinical Trial.

5

Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B-Cell Malignancies.

Ou YC, Liu L, Tariq B, Wang K, Jindal A, Tang Z, Gao Y, Sahasranaman S. Ou YC, et al. Among authors: tang z. Clin Transl Sci. 2021 Mar;14(2):764-772. doi: 10.1111/cts.12948. Epub 2021 Jan 25. Clin Transl Sci. 2021. PMID: 33306268 Free PMC article.

6

Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P-gp and BCRP.

Ou YC, Tang Z, Novotny W, Tawashi M, Li TK, Coleman HA, Sahasranaman S. Ou YC, et al. Among authors: tang z. Br J Clin Pharmacol. 2021 Jul;87(7):2926-2936. doi: 10.1111/bcp.14707. Epub 2021 Jan 14. Br J Clin Pharmacol. 2021. PMID: 33336408 Free PMC article.

7

Human Mass Balance and Metabolite Profiling of [¹⁴ C]-Pamiparib, a Poly (ADP-Ribose) Polymerase Inhibitor, in Patients With Advanced Cancer.

Mu S, Palmer D, Fitzgerald R, Andreu-Vieyra C, Zhang H, Tang Z, Su D, Sahasranaman S. Mu S, et al. Among authors: tang z. Clin Pharmacol Drug Dev. 2021 Sep;10(9):1108-1120. doi: 10.1002/cpdd.943. Epub 2021 Apr 19. Clin Pharmacol Drug Dev. 2021. PMID: 33876576 Free PMC article. Clinical Trial.

8

Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma.

Ou YC, Tang Z, Novotny W, Cohen A, Wang K, Liu L, Gao Y, Sahasranaman S. Ou YC, et al. Among authors: tang z. Leuk Lymphoma. 2021 Nov;62(11):2612-2624. doi: 10.1080/10428194.2021.1929961. Epub 2021 Jun 23. Leuk Lymphoma. 2021. PMID: 34159878 Clinical Trial.

9

In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor.

Zhang H, Ou YC, Su D, Wang F, Wang L, Sahasranaman S, Tang Z. Zhang H, et al. Among authors: tang z. Pharmacol Res Perspect. 2021 Dec;9(6):e00870. doi: 10.1002/prp2.870. Pharmacol Res Perspect. 2021. PMID: 34664792 Free PMC article.

10

A two-part, single-arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B-cell malignancies.

Song Y, Sun M, Qi J, Xu W, Zhou J, Li D, Li J, Qiu L, Du C, Guo H, Huang J, Tang Z, Ou Y, Wu B, Yu Y, Zhu J. Song Y, et al. Among authors: tang z. Br J Haematol. 2022 Jul;198(1):62-72. doi: 10.1111/bjh.18162. Epub 2022 Apr 5. Br J Haematol. 2022. PMID: 35383885 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

12,525 results

Search Page

Filters